Should I buy or sell OptimizeRx stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OPRX shares. View OPRX analyst ratings or view top-rated stocks .

What is OptimizeRx's stock price target for 2024?

7 equities research analysts have issued 12 month price objectives for OptimizeRx's shares. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.86 in the next year. This suggests a possible upside of 70.1% from the stock's current price. View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts .

How have OPRX shares performed in 2024?

OptimizeRx's stock was trading at $14.31 on January 1st, 2024. Since then, OPRX stock has decreased by 34.9% and is now trading at $9.32. View the best growth stocks for 2024 here .

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our OPRX earnings forecast .

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) posted its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.13 by $0.04. The firm earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%. During the same period last year, the company posted ($0.01) earnings per share.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD) . Global X Telemedicine & Digital Health ETF (EDOC) .

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $110.4 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC) , Bank of Hawaii (BOH) , NVIDIA (NVDA) , STAG Industrial (STAG) , Etsy (ETSY) , Marvell Technology (MRVL) , Trade Desk (TTD) , Verizon Communications (VZ) , Advanced Micro Devices (AMD) and Amgen (AMGN) .

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free OPRX Stock Alerts

$9.32

-0.03 (-0.32%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.17
▼
$9.56
50-Day Range: $9.35
▼
$16.17
52-Week Range: $6.92
▼
$16.65

Volume: 298,861 shs
Average Volume: 121,676 shs
Market Capitalization: $169.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.86

Get OptimizeRx alerts:

OptimizeRx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 70.1% Upside
$15.86 Price Target
Short Interest: Healthy
4.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.15
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.37) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Computer And Technology Sector

379th out of 585 stocks

Business Services, Not Elsewhere Classified Industry

64th out of 89 stocks

3.4

Analyst's Opinion

Consensus Rating
OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
OptimizeRx has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.10% of the float of OptimizeRx has been sold short.
Short Interest Ratio / Days to Cover
OptimizeRx has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in OptimizeRx has recently decreased by 13.08%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
OptimizeRx does not currently pay a dividend.
Dividend Growth
OptimizeRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OPRX.

2.3

News and Social Media Coverage

News Sentiment
OptimizeRx has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for OptimizeRx this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for OPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
3 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OptimizeRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of OptimizeRx is held by insiders.
Percentage Held by Institutions
76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for OptimizeRx are expected to grow in the coming year, from ($0.57) to ($0.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of OptimizeRx is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of OptimizeRx is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
OptimizeRx has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About OptimizeRx Stock (NASDAQ:OPRX)

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow. The company also offers Social Network Banner Messaging solution to deliver banner messaging to HCPs within their social network apps; Institutional Account-based Banner Messaging solution that provides its clients access to delivering banner messaging online and on the intranets of targeted health system accounts; and Financial Messaging solution, which provides prescribers visibility to branded copay offers and other patient support programs directly within their electronic health record and/or e-Prescribe systems. In addition, it provides Patient Engagement, a technology solution that provides digital messaging services through its cloud-based Mobile Health Messenger platform; HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance; and Therapy Initiation Workflow, a group of digital solutions that focuses on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was founded in 2006 and is headquartered in Rochester, Michigan.

OPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OPRX Stock News Headlines

April 18, 2024 | globenewswire.com

OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report

April 18, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for OptimizeRx Co. Decreased by William Blair (NASDAQ:OPRX)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 17, 2024 | americanbankingnews.com

OptimizeRx (NASDAQ:OPRX) Receives "Market Outperform" Rating from JMP Securities

April 16, 2024 | globenewswire.com

OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results

April 13, 2024 | stockhouse.com

OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row

April 12, 2024 | americanbankingnews.com

OptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of "Moderate Buy" by Analysts

April 11, 2024 | finance.yahoo.com

OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 11, 2024 | finance.yahoo.com

OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row

April 11, 2024 | globenewswire.com

OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row

April 11, 2024 | americanbankingnews.com

OptimizeRx (NASDAQ:OPRX) & SPAR Group (NASDAQ:SGRP) Critical Comparison

April 6, 2024 | investorplace.com

7 Top Undervalued Stocks Primed for a Multibagger Recovery

April 4, 2024 | markets.businessinsider.com

OptimizeRx: A Strong Buy on Strategic Acquisitions and Innovative Platform Expansion

April 2, 2024 | au.lifestyle.yahoo.com

Tesla blames sales drop on Houthi attacks and arson in Germany

April 1, 2024 | msn.com

Ariana Madix To Host ‘Love Island USA’ as Sarah Hyland Departs Franchise

April 1, 2024 | au.news.yahoo.com

Canoo spent double its annual revenue on the CEO’s private jet in 2023

April 1, 2024 | finance.yahoo.com

OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript

March 29, 2024 | finance.yahoo.com

Q4 2023 OPTIMIZERx Corp Earnings Call

March 28, 2024 | investorplace.com

OPRX Stock Earnings: OptimizeRx Beats Revenue for Q4 2023

March 28, 2024 | msn.com

OptimizeRx Q4 revenue $28.4M

March 27, 2024 | msn.com

OptimizeRx Q4 2023 Earnings Preview

March 27, 2024 | benzinga.com

7OPRX : OptimizeRx Earnings Preview

March 25, 2024 | globenewswire.com

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET

March 23, 2024 | seekingalpha.com

OptimizeRx: Exponential Growth Drives The Valuation Cheaper

March 13, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), AnaptysBio (ANAB) and REPRO-MED Systems (KRMD)

March 11, 2024 | markets.businessinsider.com

OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023

See More Headlines

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Computer and Technology
Industry: Business services, not elsewhere classified
Sub-Industry: N/A
Current Symbol: NASDAQ:OPRX
CUSIP: N/A
CIK: 1448431
Web: www.optimizerx.com
Phone: (248) 651-6568
Fax: 248-453-5529
Employees: 109
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.86
High Stock Price Target: $20.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +70.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-11,440,000.00
Net Margins: -21.88%
Pretax Margin: -21.88%
Return on Equity: -9.24%
Return on Assets: -8.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.35
Quick Ratio: 11.35

Sales & Book Value

Annual Sales: $71.52 million
Price / Sales: 2.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.35 per share
Price / Book: 1.27

Miscellaneous

Outstanding Shares: 18,180,000
Free Float: 17,384,000
Market Cap: $169.26 million
Optionable: Optionable
Beta: 0.98

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. William J. Febbo (Age 55)
CEO & Director
Comp: $694.4k
Mr. Stephen L. Silvestro (Age 46)
President
Comp: $458.6k
Mr. Edward Stelmakh C.M.A. (Age 58)
M.B.A., CFO & COO
Comp: $547.05k
Mr. Andrew Jacob D'Silva
Senior Vice President of Corporate Finance
Mr. Todd Inman (Age 68)
Chief Technology Officer
Ms. Marion K Odence-Ford (Age 59)
General Counsel & Chief Compliance Officer
Comp: $428.12k
Maira Alejandra
Media Relations Manager
Ms. Sheryl Kearney
Human Resources Manager
Mr. Terence J. Hamilton (Age 59)
Senior Vice President of Pharma
Comp: $441.63k
Dr. Doug Besch (Age 42)
Chief Product Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OPRX shares.
View OPRX analyst ratings or view top-rated stocks.
What is OptimizeRx's stock price target for 2024?: 7 equities research analysts have issued 12 month price objectives for OptimizeRx's shares. Their OPRX share price targets range from $13.00 to $20.00. On average, they predict the company's share price to reach $15.86 in the next year. This suggests a possible upside of 70.1% from the stock's current price.
View analysts price targets for OPRX or view top-rated stocks among Wall Street analysts.
How have OPRX shares performed in 2024?: OptimizeRx's stock was trading at $14.31 on January 1st, 2024. Since then, OPRX stock has decreased by 34.9% and is now trading at $9.32.
View the best growth stocks for 2024 here.
When is OptimizeRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our OPRX earnings forecast.
How were OptimizeRx's earnings last quarter?: OptimizeRx Co. (NASDAQ:OPRX) posted its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.13 by $0.04. The firm earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a negative trailing twelve-month return on equity of 9.24% and a negative net margin of 21.88%. During the same period last year, the company posted ($0.01) earnings per share.

What ETFs hold OptimizeRx's stock?: ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD).Global X Telemedicine & Digital Health ETF (EDOC).
What guidance has OptimizeRx issued on next quarter's earnings?: OptimizeRx updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $100.0 million-, compared to the consensus revenue estimate of $110.4 million.
What other stocks do shareholders of OptimizeRx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).
How do I buy shares of OptimizeRx?: Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OPRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial